Suppr超能文献

镰状细胞病的小鼠模型:不完美但却非常有信息价值。

Mouse models of sickle cell disease: Imperfect and yet very informative.

机构信息

Department of Perioperative Medicine, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.

Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Blood Cells Mol Dis. 2024 Jan;104:102776. doi: 10.1016/j.bcmd.2023.102776. Epub 2023 Jun 17.

Abstract

The root cause of sickle cell disease (SCD) has been known for nearly a century, however, few therapies to treat the disease are available. Over several decades of work, with advances in gene editing technology and after several iterations of mice with differing genotype/phenotype relationships, researchers have developed humanized SCD mouse models. However, while a large body of preclinical studies has led to huge gains in basic science knowledge about SCD in mice, this knowledge has not led to the development of effective therapies to treat SCD-related complications in humans, thus leading to frustration with the paucity of translational progress in the SCD field. The use of mouse models to study human diseases is based on the genetic and phenotypic similarities between mouse and humans (face validity). The Berkeley and Townes SCD mice express only human globin chains and no mouse hemoglobin. With this genetic composition, these models present many phenotypic similarities, but also significant discrepancies that should be considered when interpreting preclinical studies results. Reviewing genetic and phenotypic similarities and discrepancies and examining studies that have translated to humans and those that have not, offer a better perspective of construct, face, and predictive validities of humanized SCD mouse models.

摘要

镰状细胞病 (SCD) 的根本原因已经为人所知近一个世纪,但可用的治疗该病的疗法却寥寥无几。经过几十年的工作,随着基因编辑技术的进步以及对具有不同基因型/表型关系的老鼠进行了几轮迭代,研究人员开发了人源化 SCD 小鼠模型。然而,尽管大量的临床前研究使人们对 SCD 小鼠的基础科学知识有了巨大的提高,但这些知识并未导致针对人类 SCD 相关并发症的有效疗法的开发,从而导致 SCD 领域的转化进展乏善可陈。使用小鼠模型来研究人类疾病是基于小鼠和人类之间的遗传和表型相似性(表面有效性)。伯克利和汤斯 SCD 小鼠仅表达人类珠蛋白链,而不表达任何小鼠血红蛋白。具有这种遗传组成,这些模型具有许多表型相似之处,但也存在明显的差异,在解释临床前研究结果时应考虑这些差异。回顾遗传和表型的相似性和差异,并检查已转化为人类的研究和未转化的研究,可以更好地了解人源化 SCD 小鼠模型的构建、表面和预测有效性。

相似文献

1
Mouse models of sickle cell disease: Imperfect and yet very informative.
Blood Cells Mol Dis. 2024 Jan;104:102776. doi: 10.1016/j.bcmd.2023.102776. Epub 2023 Jun 17.
2
Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.
Am J Physiol Cell Physiol. 2022 Aug 1;323(2):C494-C504. doi: 10.1152/ajpcell.00175.2022. Epub 2022 Jun 27.
3
Sickle cell disease in mice is associated with sensitization of sensory nerve fibers.
Exp Biol Med (Maywood). 2015 Jan;240(1):87-98. doi: 10.1177/1535370214544275. Epub 2014 Jul 28.
4
Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations.
Dis Model Mech. 2022 Jun 1;15(6). doi: 10.1242/dmm.049463. Epub 2022 Jul 6.
6
Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models - Of mice and men.
Blood Cells Mol Dis. 2025 Mar;111:102909. doi: 10.1016/j.bcmd.2025.102909. Epub 2025 Jan 16.
7
Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.
Antioxid Redox Signal. 2016 Dec 10;25(17):921-935. doi: 10.1089/ars.2016.6638. Epub 2016 Aug 22.
8
The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice.
PLoS One. 2025 May 13;20(5):e0323550. doi: 10.1371/journal.pone.0323550. eCollection 2025.
9
In vivo HSC prime editing rescues sickle cell disease in a mouse model.
Blood. 2023 Apr 27;141(17):2085-2099. doi: 10.1182/blood.2022018252.
10
From early development to maturity: a phenotypic analysis of the Townes sickle cell disease mice.
Biol Open. 2025 Feb 15;14(2). doi: 10.1242/bio.061828. Epub 2025 Feb 6.

引用本文的文献

1
Decitabine-Driven Foetal Haemoglobin Induction in Townes Mice and Human Erythroblasts.
EJHaem. 2025 Aug 4;6(4):e70120. doi: 10.1002/jha2.70120. eCollection 2025 Aug.
4
Targeting sickle cell pathobiology and pain with novel transdermal curcumin.
PNAS Nexus. 2025 Feb 13;4(2):pgaf053. doi: 10.1093/pnasnexus/pgaf053. eCollection 2025 Feb.
5
From early development to maturity: a phenotypic analysis of the Townes sickle cell disease mice.
Biol Open. 2025 Feb 15;14(2). doi: 10.1242/bio.061828. Epub 2025 Feb 6.
6
Challenges and opportunities for conceiving genetically diverse sickle cell mice.
Trends Mol Med. 2025 May;31(5):413-423. doi: 10.1016/j.molmed.2024.11.004. Epub 2024 Dec 5.
8
Calcium flux alterations in erythrocytes from sickle cell mice: The relevance of mean corpuscular volume.
Blood Cells Mol Dis. 2024 Jan;104:102800. doi: 10.1016/j.bcmd.2023.102800. Epub 2023 Nov 2.
9
Sickle Cell Disease and CKD: An Update.
Am J Nephrol. 2024;55(1):56-71. doi: 10.1159/000534865. Epub 2023 Oct 27.

本文引用的文献

1
Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients.
Blood Adv. 2023 May 9;7(9):1762-1768. doi: 10.1182/bloodadvances.2022007802.
2
Effects of GBT1118, a voxelotor analog, on intestinal pathophysiology in sickle cell disease.
Br J Haematol. 2023 Jul;202(1):184-194. doi: 10.1111/bjh.18813. Epub 2023 Apr 13.
3
The inflammatory profiles of pulmonary alveolar macrophages and alveolar type 2 cells in SCD.
Exp Biol Med (Maywood). 2023 Jun;248(12):1013-1023. doi: 10.1177/15353702231157940. Epub 2023 Apr 3.
4
5
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Br J Haematol. 2023 Jul;202(1):173-183. doi: 10.1111/bjh.18771. Epub 2023 Mar 24.
7
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries.
Blood Adv. 2023 Jul 11;7(13):3276-3283. doi: 10.1182/bloodadvances.2022009202.
8
Peripheral transient receptor potential vanilloid type 4 hypersensitivity contributes to chronic sickle cell disease pain.
Pain. 2023 Aug 1;164(8):1874-1886. doi: 10.1097/j.pain.0000000000002889. Epub 2023 Mar 10.
9
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.
Hemasphere. 2023 Feb 28;7(3):e848. doi: 10.1097/HS9.0000000000000848. eCollection 2023 Mar.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验